Merck (MRK) and Eisai Announces EU Approval of LENVIMA Plus KEYTRUDA as First-Line Treatment for Adult Patients With Advanced Renal Cell Carcinoma
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
| Merck & Co. (NYSE: MRK) | Delayed: 140.61 -4.66 (3.21%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $145.27 | 52 Week High | $65.46 | |||
| Open | $145.89 | 52 Week Low | $47.97 | |||
| Day High | $146.61 | P/E | 95.65 | |||
| Day Low | $139.93 | EPS | $1.47 | |||
| Volume | 13,105,919 | |||||
